Status:
COMPLETED
A Comprehensive HBsAg-positive Patients Centered Screening Strategy
Lead Sponsor:
Hong Ren
Collaborating Sponsors:
Gilead Sciences
Conditions:
Hepatitis B and Hepatitis C (Disorder)
Eligibility:
All Genders
Brief Summary
HBV(hepatitis B virus) /HCV(hepatitis C virus) co-infection may accelerate liver disease progression and increase the risk of HCC(Hepatocellular Carcinoma)development. It is reported HCV co-infection ...
Detailed Description
1\. Objective: Primary objective: Evaluate value of HCV education in HCV screening and diagnosis in HBsAg(+) patients Secondary objectives: 1. Evaluate prevalence of HCV co-infection in HBV cohort...
Eligibility Criteria
Inclusion
- HBsAg(+) patients
Exclusion
- none
Key Trial Info
Start Date :
February 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT03794791
Start Date
February 20 2019
End Date
December 31 2020
Last Update
January 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The 2nd affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400010